文献速递关节外科

全髋关节置换术前治疗丙型肝炎具有成本效益:一项马尔可夫分析

Treating Hepatitis C Prior to Total Hip Arthroplasty is Cost-effective: A Markov Analysis.
PubMed 文献 · J Arthroplasty · 2023-03-05

该马尔可夫模型比较丙型肝炎病毒(HCV)阳性患者全髋关节置换(THA)术前不治疗与直接抗病毒药物(DAA)治疗的成本效益,结果显示DAA治疗组增量成本效益比为13,800美元/QALY,低于50,000美元/QALY的支付意愿阈值,作者认为在所有当前药品目录价格下均具有成本效益。

要点

  • HCV阳性患者THA术前DAA治疗较不治疗增量成本效益比为13,800美元/QALY。
  • DAA治疗组增加14.39质量调整生命年(QALY),不治疗组增加8.06 QALY。
  • DAA治疗组平均成本115,800美元,不治疗组平均成本28,800美元。

核心结论

  • 在THA术前使用DAA治疗HCV在所有当前药品目录价格下均具有成本效益。
  • 基于这些发现,作者认为应强烈考虑在择期THA前对患者进行HCV治疗。

研究设计与样本

  • 采用马尔可夫模型评估HCV阳性患者THA术前使用DAA治疗与不治疗的成本效益。
  • 模型参数(事件概率、死亡率、成本和QALY值)来自已发表文献,包括治疗成本、HCV根除成功率、浅表或假体周围感染(PJI)发生率、各种PJI治疗模式的使用概率、PJI治疗成功/失败率和死亡率。
  • 增量成本效益比与50,000美元/QALY的支付意愿阈值进行比较。
  • 证据等级:成本效益分析;III级。

主要发现

  • 不治疗组THA增加8.06 QALY,平均成本28,800美元;DAA治疗组增加14.39 QALY,平均成本115,800美元。
  • DAA治疗相比不治疗的增量成本效益比为13,800美元/QALY,低于50,000美元/QALY的支付意愿阈值。

关键数值与推荐

  • 增量成本效益比13,800美元/QALY,低于支付意愿阈值50,000美元/QALY。

临床怎么用

  • 作者认为,基于这些发现应强烈考虑在择期THA前对患者进行HCV治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients infected with the hepatitis C virus (HCV) have high complication rates following total hip arthroplasty (THA). Advances in HCV therapy now enable clinicians to eradicate the disease; however, its cost-effectiveness from an orthopaedic perspective remains to be demonstrated. We sought to conduct a cost-effectiveness analysis comparing no therapy to direct-acting antiviral (DAA) therapy prior to THA among HCV-positive patients. METHODS: A Markov model was utilized to evaluate the cost-effectiveness of treating HCV with DAA prior to THA. The model was powered with event probabilities, mortality, cost, and quality-adjusted life year (QALY) values for patients with and without HCV that were obtained from the published literature. This included treatment costs, successes of HCV eradication, incidences of superficial or periprosthetic joint infection (PJI), probabilities of utilizing various PJI treatment modalities, PJI treatment success/failures, and mortality rates. The incremental cost-effectiveness ratio was compared to a willingness-to-pay threshold of $50,000/QALY. RESULTS: Our Markov model indicates that in comparison to no therapy, DAA prior to THA is cost-effective for HCV-positive patients. THA in the setting of no therapy and DAA added 8.06 and 14.39 QALYs at a mean cost of $28,800 and $115,800. The incremental cost-effectiveness ratio associated with HCV DAA in comparison to no therapy was $13,800/QALY, below the willingness-to-pay threshold of $50,000/QALY. CONCLUSION: Hepatitis C treatment with DAA prior to THA is cost-effective at all current drug list prices. Given these findings, strong consideration should be given to treating patients for HCV prior to elective THA. LEVEL OF EVIDENCE: Cost-effectiveness Analysis; Level III.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Anoushiravani AA, Kalyanasundaram G, Feng JE, et al. Treating Hepatitis C Prior to Total Hip Arthroplasty is Cost-effective: A Markov Analysis. J Arthroplasty. 2023. PMID: 36878438. doi:10.1016/j.arth.2023.02.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。